agilon health (NYSE:AGL) Price Target Cut to $2.00 by Analysts at TD Cowen

agilon health (NYSE:AGL) had its price target reduced by TD Cowen from $6.00 to $2.00 in a research report released on Monday,Benzinga reports. TD Cowen currently has a hold rating on the stock.

A number of other equities analysts also recently weighed in on the stock. Deutsche Bank Aktiengesellschaft lowered their target price on shares of agilon health from $5.00 to $4.00 and set a “hold” rating on the stock in a report on Friday, August 9th. Barclays lowered their target price on shares of agilon health from $5.00 to $2.00 and set an “underweight” rating on the stock in a report on Monday. Citigroup reaffirmed a “sell” rating and set a $2.50 price objective (down from $7.00) on shares of agilon health in a research report on Tuesday, October 29th. Evercore ISI reduced their price objective on shares of agilon health from $7.00 to $4.00 and set an “in-line” rating for the company in a research report on Tuesday, October 8th. Finally, JMP Securities cut shares of agilon health from an “outperform” rating to a “market perform” rating in a research report on Monday. Three research analysts have rated the stock with a sell rating, fifteen have given a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $7.34.

agilon health Price Performance

NYSE AGL opened at $2.16 on Monday. The company has a quick ratio of 1.36, a current ratio of 1.36 and a debt-to-equity ratio of 0.04. agilon health has a 12-month low of $1.80 and a 12-month high of $13.76. The company has a market capitalization of $888.80 million, a PE ratio of -2.30 and a beta of 0.60. The firm’s 50 day moving average is $3.22 and its 200-day moving average is $4.95.

agilon health (NYSE:AGL) last issued its earnings results on Thursday, November 7th. The company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.19). The firm had revenue of $1.45 billion for the quarter, compared to analyst estimates of $1.47 billion. agilon health had a negative return on equity of 46.06% and a negative net margin of 6.88%. During the same quarter in the previous year, the firm posted ($0.06) earnings per share. Equities research analysts anticipate that agilon health will post -0.32 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Steven Sell acquired 20,000 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The stock was acquired at an average price of $3.36 per share, with a total value of $67,200.00. Following the completion of the transaction, the chief executive officer now directly owns 67,590 shares of the company’s stock, valued at $227,102.40. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 3.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On agilon health

Several institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in agilon health by 1.3% during the first quarter. Vanguard Group Inc. now owns 28,947,798 shares of the company’s stock worth $176,582,000 after acquiring an additional 371,537 shares in the last quarter. Capital International Investors raised its stake in agilon health by 84.7% during the first quarter. Capital International Investors now owns 20,197,932 shares of the company’s stock worth $123,207,000 after acquiring an additional 9,263,296 shares in the last quarter. AQR Capital Management LLC raised its stake in agilon health by 3,338.5% during the second quarter. AQR Capital Management LLC now owns 1,356,438 shares of the company’s stock worth $8,871,000 after acquiring an additional 1,316,990 shares in the last quarter. Bank of New York Mellon Corp raised its stake in agilon health by 18.7% during the second quarter. Bank of New York Mellon Corp now owns 1,108,921 shares of the company’s stock worth $7,252,000 after acquiring an additional 174,883 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC raised its stake in agilon health by 65.0% during the second quarter. Susquehanna Fundamental Investments LLC now owns 804,594 shares of the company’s stock worth $5,262,000 after acquiring an additional 316,856 shares in the last quarter.

About agilon health

agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc and changed its name to agilon health, inc.